Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 7/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 4/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6462719 | 0.90 | MMP12 (0.64) | MMP12MMP13EPHX2NR1H4PPARA | |
| SCHEMBL6456507 | 0.89 | MMP12 (0.72) | MMP12MMP13EPHX2NR1H4PPARA | |
| SCHEMBL6458023 | 0.89 | MMP12 (0.56) | MMP12MMP13NR1H4PPARAMAPK1 | |
| SCHEMBL6667161 | 0.88 | MMP12 (0.60) | MMP12MMP13EPHX2NR1H4PPARA | |
| SCHEMBL6874175 | 0.88 | MMP12 (0.57) | MMP12MMP13EPHX2NR1H4PPARA | |
| SCHEMBL8337355 | 0.88 | MMP12 (0.60) | MMP12MMP13EPHX2NR1H4PPARA | |
| SCHEMBL6457608 | 0.86 | MMP12 (0.55) | MMP12MMP13PPARAMAPK1ROCK2 | |
| SCHEMBL6881373 | 0.86 | MMP12 (0.55) | MMP12MMP13EPHX2NR1H4PPARA | |
| SCHEMBL6455464 | 0.86 | NPC1 (0.61) | MMP12MMP13EPHX2NR1H4PPARG | |
| SCHEMBL6456642 | 0.83 | MMP12 (0.56) | MMP12MMP13EPHX2NR1H4PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | claimed |
| EP-1394159-A1 | New thiophene derivatives, process for their preparation and pharmaceutical compositions containing them | Warner-Lambert Company LLC (US) | 2004-03-03 | — | — | EP | claimed |
| US-20040171543-A1 | Matrix metalloproteinase inhibitors and methods for identification of lead compounds | WARNER-LAMBERT COMPANY LLC | 2004-09-02 | — | — | US | disclosed |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | disclosed |
| EP-1394159-A1 | New thiophene derivatives, process for their preparation and pharmaceutical compositions containing them | Warner-Lambert Company LLC (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2004014381-A2 | MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR IDENTIFICATION OF LEAD COMPOUNDS | WARNER-LAMBERT COMPANY LLC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014867-A2 | MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR IDENTIFICATION OF LEAD COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171543-A1 | Matrix metalloproteinase inhibitors and methods for identification of lead compounds | MMP13, MMP3, MMP26 | MMP12 4/4885MMP13 1/4885EPHX2 1992/4885 |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | MMP11, MMP13, CBR1 | MMP12 7/4885MMP13 2/4885EPHX2 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.